Use of Early Remdesivir to Prevent Progression of COVID-19 to Severe Disease When Given in the Outpatient Setting
This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
We are all at risk for exposure to SARS-CoV-2, and we know too well our increased probability of serious illness and even death if we develop a symptomatic case of COVID-19.
Though the 90% hospitalization rate and 1 in 3 mortality rate reported in medical literature were reported from research done early in the pandemic and outcomes are certainly better now, our risks remain substantial. See: COVID-19 severity and mortality in chronic lymphocytic leukemia (CLL) patients
Some jobs are higher risk than others for exposure to SARS-CoV-2.
In our interview, my doctor, Dr. John Byrd from The Ohio State University, Columbus, OH, gives his detailed advice for first responders, doctors, and teachers.
He tells us that he is writing many notes for patients to take to their employers to find an alternative and safer work environment. He asks you to plan ahead about your work safety needs, to help your doctor help you, but do ask for the note if you need it.
To that end, CLL Society has produced our CLL Society’s Official Statement Concerning CLL (chronic lymphocytic leukemia) Patients Working and Traveling During the COVID-19 Pandemic to help your HR department better understand your special circumstances.
Please hear what Dr. Byrd has to say about those CLL patients whose work puts them at higher risk for exposure to COVID-19. It is wise counsel.
Stay strong.
We are all in this together.
Brian
Brian Koffman MDCM (retired) MS Ed
Co-Founder, Executive VP and Chief Medical Officer
CLL Society, Inc.
This program was made possible by support from:
Related posts
